Diffuse large B-cell lymphoma (DLBCL) | Flatiron Health

Real-world outcomes of patients with Diffuse Large B-Cell Lymphoma receiving second line therapy in the United States →

Sawas, A, Lau, C, Thomson, M, Maignan, K

December 2020

American Society of Hematology Annual Meeting

Flatiron-authored

Real-world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies →

Ayers, EC, Margolis, DJ, Landsburg, DJ

May 2020

Clinical Lymphoma; Myeloma; and Leukemia

Cell of origin (COO) association with high body mass index (BMI) and overall survival (OS) in patients with diffuse large b-cell lymphoma (DLBCL) →

Maignan, K, Azzam, SP, Adamson, BJS, Parrinello, CM

December 2019

American Society of Hematology Annual Meeting

Flatiron-authored

Real-world application of National Comprehensive Cancer Network (NCCN) testing guidelines in diffuse large B-cell lymphoma (DLBCL) results in underdiagnosis of double-hit lymphoma →

Hooley, IJ, Parrinello, CM, Opong, A, Maignan, K, Fisher, R

December 2019

American Society of Hematology Annual Meeting

Flatiron-authored

Real-world outcomes of patients with relapsed/refractory diffuse large B cell lymphoma who receive commercially-available salvage therapy →

Ayers, EC, Margolis, DJ, Gimotty, PA, Landsburg, DJ

December 2019

American Society of Hematology Annual Meeting

Real-world prognostic impact of BCL2 and MYC expression and translocation among diffuse large B-cell lymphoma patients treated with first-line R-chop →

Downer, MK, Chaudhary, N, Szafer-Glusman, E, Breuleux, M, Hsi, ED, Biondo, J, Bazeos, A, Jiang, Y

June 2019

International Conference on Malignant Lymphoma

Prognostic impact of BCL2 and MYC expression and translocation among newly diagnosed diffuse large B-cell lymphoma patients with R-chop in the real world →

Downer, MK, Chaudhary, N, Breuleux, M, Szafer-Glusman, E, Hsi, ED, Biondo, J, Jiang, Y

June 2019

Congress of the European Hematology Association